MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
PLX Protalix Biotherapeutics
- 1.760
- +0.020+1.15%
Close Dec 20 16:00 ET
- 1.760
- 0.0000.00%
Post 18:22 ET
129.60MMarket Cap-11.73P/E (TTM)
1.785High1.690Low344.36KVolume1.690Open1.740Pre Close601.48KTurnover0.63%Turnover Ratio19.56P/E (Static)73.63MShares1.90052wk High3.99P/B96.36MFloat Cap0.82152wk Low--Dividend TTM54.75MShs Float1037.500Historical High--Div YieldTTM5.46%Amplitude0.700Historical Low1.746Avg Price1Lot Size
Protalix Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 159.60%4.11M | -172.59%-3.61M | 239.69%4.19M | 94.73%-1.32M | 237.69%3.6M | 25.16%-6.89M | 167.60%4.97M | 48.57%-3M | -143.07%-25M | 48.67%-2.61M |
| Net income from continuing operations | 274.73%3.24M | -111.39%-2.2M | -46.76%-4.6M | 155.68%8.31M | -61.60%-6.04M | 48.08%-1.85M | 462.56%19.34M | -36.96%-3.13M | 45.88%-14.93M | 43.90%-3.74M |
| Operating gains losses | 102.78%3K | 109.09%1K | -75.00%5K | 92.96%-38K | 139.35%61K | -325.00%-108K | 97.88%-11K | -76.47%20K | -166.42%-540K | -2,037.50%-155K |
| Depreciation and amortization | 7.87%329K | 8.87%319K | 15.00%322K | 9.67%1.19M | 13.82%313K | 11.72%305K | 9.33%293K | 3.70%280K | -2.86%1.09M | 6.18%275K |
| Deferred tax | 1,065.79%443K | 97.80%-69K | ---138K | ---3.09M | --0 | --38K | ---3.13M | --0 | --0 | --0 |
| Other non cash items | 483.95%1.15M | -21.74%-504K | -4,181.82%-471K | 12.92%-600K | -27.06%124K | -464.15%-299K | 39.39%-414K | 91.06%-11K | -122.30%-689K | -57.82%170K |
| Change In working capital | 72.42%-1.67M | 81.36%-2.15M | 1,251.57%8.08M | 12.28%-10.54M | 2,491.33%7.77M | 4.08%-6.07M | -738.20%-11.54M | 84.78%-702K | -221.35%-12.02M | -39.02%300K |
| -Change in receivables | 294.50%8.38M | -90.44%-7.05M | -54.33%1.75M | 64.15%-428K | -16.41%3.76M | 25.33%-4.31M | -254.98%-3.7M | 265.21%3.82M | -15.70%-1.19M | 47.81%4.5M |
| -Change in inventory | 280.70%3.52M | 143.56%1.63M | 5.66%-3.3M | -294.87%-2.24M | 213.20%2.54M | -200.15%-1.95M | 667.82%668K | -357.28%-3.5M | 123.60%1.15M | 30.46%-2.24M |
| -Change in payables and accrued expense | -590.96%-869K | -50.97%1.61M | -500.57%-1.41M | 210.22%5.3M | 503.01%1.48M | -58.45%177K | 185.39%3.29M | 134.92%353K | -301.43%-4.8M | -127.83%-366K |
| -Change in other current assets | -177.78%-7K | 200.00%6K | 55.56%14K | 360.00%13K | -96.00%1K | 133.33%9K | ---6K | --9K | -102.07%-5K | -65.75%25K |
| -Change in other current liabilities | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| -Change in other working capital | ---- | 114.05%1.66M | 895.32%11.04M | -84.00%-13.18M | --0 | --0 | -589,600.00%-11.79M | 47.54%-1.39M | -154.13%-7.16M | -125.87%-1.62M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 159.60%4.11M | -172.59%-3.61M | 239.69%4.19M | 94.73%-1.32M | 237.69%3.6M | 25.16%-6.89M | 167.60%4.97M | 48.57%-3M | -143.07%-25M | 48.67%-2.61M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 197.36%20.33M | 18.92%-180K | -112.81%-606K | -231.90%-16.71M | -106.90%-342K | -453.16%-20.88M | -162.18%-222K | 129.11%4.73M | -126.61%-5.04M | -86.77%4.95M |
| Net PPE purchase and sale | 81.21%-84K | 15.69%-172K | -141.13%-598K | -82.96%-1.15M | -17.37%-250K | -670.69%-447K | -59.38%-204K | -8.30%-248K | 55.33%-628K | 52.46%-213K |
| Net investment purchase and sale | ---- | ---- | ---- | -208.40%-15.42M | --0 | -440.33%-20.42M | --0 | 131.25%5M | -125.00%-5M | -86.78%5M |
| Net other investing changes | 25.00%-9K | 55.56%-8K | 60.00%-8K | -123.95%-142K | -155.42%-92K | 60.00%-12K | -103.71%-18K | 28.57%-20K | 81.35%593K | 238.78%166K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 197.36%20.33M | 18.92%-180K | -112.81%-606K | -231.90%-16.71M | -106.90%-342K | -453.16%-20.88M | -162.18%-222K | 129.11%4.73M | -126.61%-5.04M | -86.77%4.95M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -20.42M | 0 | 0 | 199.42%24.67M | 0 | 0 | 10.43M | 14.23M | -31.79%8.24M | 200.72%4.08M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Net common stock issuance | --0 | --0 | --0 | 190.85%23.95M | --0 | --0 | --9.72M | --14.23M | -82.17%8.24M | --4.08M |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | 35,500.00%712K | --0 | --0 | ---- | ---- | --2K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---20.42M | --0 | --0 | 199.42%24.67M | --0 | --0 | 294.74%10.43M | --14.23M | -31.79%8.24M | 200.72%4.08M |
| Net cash flow | ||||||||||
| Beginning cash position | -51.44%23.4M | -17.64%27.21M | 38.12%23.63M | -56.11%17.11M | 90.37%20.41M | 285.72%48.18M | 95.62%33.04M | -56.11%17.11M | 113.44%38.99M | 0.73%10.72M |
| Current changes in cash | 114.45%4.01M | -124.96%-3.79M | -77.57%3.58M | 130.45%6.64M | -49.31%3.25M | -1,466.99%-27.77M | 448.58%15.18M | 172.29%15.97M | -205.23%-21.8M | -77.33%6.42M |
| Effect of exchange rate changes | 77.78%-2K | 44.44%-20K | 83.33%-7K | -48.05%-114K | -3.85%-27K | ---9K | 10.00%-36K | -281.82%-42K | -1,383.33%-77K | -165.00%-26K |
| End cash Position | 34.31%27.41M | -51.44%23.4M | -17.64%27.21M | 38.12%23.63M | 38.12%23.63M | 90.37%20.41M | 285.72%48.18M | 95.62%33.04M | -56.11%17.11M | -56.11%17.11M |
| Free cash flow | 154.78%4.02M | -179.30%-3.78M | 210.60%3.59M | 90.37%-2.47M | 218.45%3.35M | 20.81%-7.34M | 163.72%4.77M | 46.42%-3.25M | -118.22%-25.63M | 48.98%-2.82M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.